Table 2.

Adverse events during the treatment period

	AZD8601 3 mg (n = 7)	Placebo (n = 4)
Any adverse event, n (%)	7 (100)	4 (100)
Related to study druga	1 (14.3)	0 (0)
Fatal adverse event, n (%)	0 (0)	0 (0)
Serious adverse event, n (%)b	2 (28.6)	0 (0)
Related to study drug	0 (0)	0 (0)
Adverse event leading to discontinuation or withdrawal, n (%)	0 (0)	0 (0)
Anemia, n (%)c	2 (28.6)	1 (25)
Atrial fibrillation, n (%)d	2 (28.6)	2 (50)
Coagulopathy, n (%)c	2 (28.6)	0 (0)
Dizziness, n (%)c	1 (14.3)	0 (0)
Dyspepsia, n (%)c	1 (14.3)	0 (0)
Dyspnea, n (%)e	1 (14.3)	0 (0)
Hypotension, n (%)c	1 (14.3)	0 (0)
Nausea, n (%)e	1 (14.3)	0 (0)
Pleural effusion, n (%)c	0 (0)	2 (50)
Procedural pain, n (%)e	0 (0)	1 (25)
Pyrexia, n (%)e	0 (0)	1 (25)
Sinus bradycardia, n (%)e	1 (14.3)	0 (0)
Urinary tract infection, n (%)e	0 (0)	1 (25)
Ventricular arrhythmia, n (%)f	1 (14.3)	0 (0)
Ventricular extrasystoles, n (%)e	1 (14.3)	0 (0)

^aVentricular arrhythmia and ventricular extrasystoles before AZD8601 administration in one patient.

^bAnemia in one patient and coagulopathy in one patient.

^cModerate maximum severity.

^dModerate maximum intensity in three patients and mild in one (in the AZD8601 group).

^eMild maximum intensity.

^fSevere maximum intensity.